AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04418362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: A home-based self-administered neurofeedback intervention taking place 4-6 times per week for 8 weeks.
Study NCT02007317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D & Oshadi R
Description: Anti tumor agents
Study NCT00700375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
Study NCT00700375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride
Description: 8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
Study NCT04571047 — intervention group
Intervention type: OTHER
Intervention: Time to treatment
Description: Treatment before or after 4 weeks after diagnosis
Study NCT02408042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Study NCT02408042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT02408042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Study NCT02408042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Study NCT02408042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT02408042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab vedotin
Study NCT02408042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT02907242 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Revealment
Description: Cerebroplacental ratio revealment
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum capsule
Description: Clostridium butyricum group: given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Study NCT01593787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 100 mg, 200 mg, 400 mg tablets.
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Esmeprazole 40mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Study NCT04287699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: labor dance
Description: The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
Study NCT02056990 — intervention group
Intervention type: OTHER
Intervention: Advice
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: Esmeprazole 40mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus esmeprazole 40mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus esmeprazole 40mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 40mg 1tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 40mg 1tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus clotting
Description: given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Study NCT05237115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Study NCT04361799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS
Description: Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
Study NCT04361799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin therapy
Description: Standard insulin therapy according to local clinical practice.
Study NCT01852123 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-sensitivity troponin I assay
Study NCT00001322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3.75
Description: Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
Study NCT00001322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Transdermal Estradiol, 100mcg/day by skin patch
Study NCT00001322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone suppository, 200mg vaginally twice/day
Study NCT00001322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suppository
Description: Placebo suppository twice daily
Study NCT00001322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Placebo by skin patch
Study NCT02027233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasopharyngeal sample
Description: The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
Study NCT03662126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth
Study NCT03662126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Best available therapy options include:~1. hydroxyurea~2. chemotherapy or~3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed).
Study NCT01999985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib - 1A
Description: 1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
Study NCT01999985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib - 1A
Description: 1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
Study NCT01999985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib - 1B
Description: In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
Study NCT01999985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib - 1B
Description: In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
Study NCT03403907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: twice a day for 4 months (Streptococcus thermophilus, Lactobacillus acidophilus, L.plantarum, L. paracasei, L. delbrueckii subs bulgaricus, Bifidobacterium breve, B.longus y B.infantis. y CD2).
Study NCT01693679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine, Lamivudine, Adefovir ,Enecavir
Description: investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
Study NCT02121795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg FDC tablets administered orally once daily
Study NCT02121795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: Tablets administered orally once daily
Study NCT02121795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allowed third antiretroviral agent
Description: An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
Study NCT02121795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allowed third antiretroviral agent
Description: An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
Study NCT02121795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: Tablets administered orally once daily
Study NCT02121795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF Placebo
Description: Tablets administered orally once daily
Study NCT01704755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
Study NCT01704755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Capsule
Study NCT04421040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotronik Biomonitor 3 implant of device
Description: The Biotronik Biomonitor 3 device will be implanted by the research team physician.
Study NCT04421040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotronik Biomonitor 3 explant of device
Description: The Biotronik Biomonitor 3 device will be removed from the patient by the research team physician.
Study NCT01725633 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Progressive Stretching Group
Description: Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
Study NCT01725633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear Aerobic Training
Description: Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
Study NCT01725633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
Study NCT01725633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
Study NCT01725633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing (CPET)
Description: At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
Study NCT01705977 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard therapy
Description: Placebo plus standard therapy
Study NCT01705977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg plus standard therapy
Description: Belimumab 10 mg/kg plus standard therapy
Study NCT01705977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
Study NCT01705977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
Study NCT00742794 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation of sting frequency
Study NCT03407313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational fractional resection (1.5mm diameter device)
Description: Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
Study NCT01396083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT01396083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone implant and sham injections
Study NCT01063855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
Study NCT01063855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Description: 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
Study NCT01063855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE5I (phosphodiesterase-5 inhibitor)
Description: Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
Study NCT01063855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PDE5I (phosphodiesterase-5 inhibitor)
Description: Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
Study NCT02843464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reported remote ischemic preconditioning (RIPC)
Description: Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
Study NCT03060304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
Study NCT03060304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
Study NCT03234036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 100 mg tablet
Description: It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
Study NCT03234036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 50 mg capsule
Description: It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
Study NCT03234036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg tablets
Description: It is a white film-coated ovaloid tablets.
Study NCT03234036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for GSK2838232 tablets
Description: It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
Study NCT00552695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine tetracaine
Description: Lidocaine 70 mg/tetracaine 70 mg
Study NCT00552695 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch identical in appearance to Synera
Study NCT02537951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFI microscope
Description: measurement of AFI intensities following increasing nociceptive stimulus intensities
Study NCT02537951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: negative control 1: lidocaine/prilocaine
Description: measurement of AFI intensities following lidocaine/prilocaine cream
Study NCT02537951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: negative control 2: 8% capsaicin
Description: measurement of AFI intensities following 8% capsaicin patch
Study NCT03600831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin
Description: cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks
Study NCT03600831 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)
Study NCT03600831 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)
Study NCT03794492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
Description: - Orally, up to 1g BID(total 2g daily)
Study NCT03794492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: - Orally, check the blood ceocentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3-8ng/ml
Study NCT03794492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone/prednisolone
Description: - Methyprednisolone 500mg / Prednisolone 5mg
Study NCT03794492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: - IV, 20mg(before Kidney transplat) / 20mg(Day 4 of kidney transplant)
Study NCT02754232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedical training
Description: Intervention will involve resistance training and anaerobic training
Study NCT01341015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.